Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Zhonghua Zhong Liu Za Zhi ; 16(1): 43-6, 1994 Jan.
Artigo em Chinês | MEDLINE | ID: mdl-8033748

RESUMO

Sixty eight cases of small cell lung carcinoma (SCLC) were treated with Combination chemotherapy regimen of COCE or COMP. Among them, 22 cases received radiotherapy after chemotherapy, and 14 cases were studied with antibodies of NSE (neuron-specific enolase), CCH-A (chromogranin A), CEA (carcino-embryonic antigen) and keratin using an immunohistochemical ABC method. The total remission rate was 58.8% and the MST was 12.8 months. The CR+PR of COCE treated group was 74.3% and the MST was 12.9 months. The CR+PR of COMP treated group was 37.8% and the MST was 10 months. There was statistically significant difference between results of the COCE and COMP-treated groups. The MST of cases who received radiotherapy after chemotherapy was 15 months (COCE 17.3 months, COMP 12 months). It indicated that COCE regimen was more effective than COMP one. The immunohistochemical result showed that 44.4% (6/14) of the cases were positive with NSE and/or CCH-A, and their MAT was longer than that of NSE and/or CCH-A negative cases. It suggests that SCLC with neuroendocrine differentiation has a better prognosis.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Idoso , Carcinoma de Células Pequenas/química , Carcinoma de Células Pequenas/radioterapia , Cromogranina A , Cromograninas/análise , Terapia Combinada , Ciclofosfamida/administração & dosagem , Etoposídeo/administração & dosagem , Feminino , Humanos , Lomustina/administração & dosagem , Neoplasias Pulmonares/química , Neoplasias Pulmonares/radioterapia , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Fosfopiruvato Hidratase/análise , Prednisona/administração & dosagem , Prognóstico , Indução de Remissão , Vincristina/administração & dosagem
2.
Zhonghua Zhong Liu Za Zhi ; 8(4): 297-9, 1986 Jul.
Artigo em Chinês | MEDLINE | ID: mdl-2428570

RESUMO

One hundred and fifteen patients with inoperable esophageal carcinoma were treated by either chemotherapy alone or chemotherapy plus Rabdosia rubescens. In group A, out of 31 patients treated with pingyangmycin (P) and nitrocaphane (N), 10 (32.3%) responded to the treatment. Among them, 2 showed partial response (greater than 50% tumor regression) and 8 minimal response (greater than 50% tumor regression). In group B, out of 84 patients treated with PN plus Rabdosia rubescens, 59 (70.2%) responded. Of them, 10 showed complete response (100% tumor regression), 16 partial response and 33 minimal response. the one-year survival rates of group A and B were 13.6% and 41.3%. Statistical significance was present in these two groups both in the response rate and one-year survival rate. As regards the drug toxicity, there was no significant difference between these two groups. Alopecia, anorexia, nausea and hyperpyrexia occurred in more than 30% of patients. Mild leukopenia and thrombocytopenia and interstitial pneumonia were noted in some patients, and two patients died of toxicity in the lungs.


Assuntos
Carcinoma de Células Escamosas/tratamento farmacológico , Neoplasias Esofágicas/tratamento farmacológico , Medicina Tradicional Chinesa , Medicina Tradicional do Leste Asiático , Plantas Medicinais , Adulto , Idoso , Antibióticos Antineoplásicos/uso terapêutico , Antineoplásicos/uso terapêutico , Bleomicina/uso terapêutico , Sinergismo Farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Compostos de Mostarda Nitrogenada/uso terapêutico , Extratos Vegetais/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa